Andrade Justin, Sessa Lauren, Ephrat Moshe, Truong James, DiGregorio Robert
Department of Pharmacy Practice, Touro College of Pharmacy, New York, NY, USA.
Pharmacotherapy Department, The Brooklyn Hospital Center, Brooklyn, NY, USA.
J Pharm Pract. 2024 Jun;37(3):753-757. doi: 10.1177/08971900221147584. Epub 2022 Dec 19.
Since the issuance of the emergency use authorization (EUA) of 3 coronavirus disease 2019 (COVID-19) vaccines, there have been over 180 million individuals fully vaccinated in the United States (US). With the increasing administration of COVID-19 vaccinations, there have been over 550,000 adverse events reported in the Vaccine Adverse Event Reporting System (VAERS) with approximately 230,000 experienced after receipt of the Pfizer-BioNTech COVID-19 Vaccine as of September 23 2021. Audio-vestibular symptoms (including Sudden Sensorineural Hearing Loss (SSNHL)) secondary to immunizations has previously been evaluated. However, this report describes the first case of bilateral sudden sensorineural hearing loss potentially due to the Pfizer-BioNTech COVID-19 vaccine. We further review the available literature regarding the treatment of Sudden Sensorineural Hearing Loss, and the association of SSNHL with previous immunizations and COVID-19 infection. Lastly, we hypothesize the underlying potential mechanisms between SSNHL and the Pfizer-BioNTech COVID-19 vaccine.
自2019冠状病毒病（COVID-19）三种疫苗的紧急使用授权发布以来，美国已有超过1.8亿人完全接种了疫苗。随着COVID-19疫苗接种量的增加，疫苗不良事件报告系统（VAERS）报告了超过55万起不良事件，截至2021年9月23日，在接种辉瑞-生物科技公司的COVID-19疫苗后约有23万起。此前已对免疫接种继发的听觉前庭症状（包括突发性感音神经性听力损失（SSNHL））进行了评估。然而，本报告描述了首例可能由辉瑞-生物科技公司的COVID-19疫苗导致的双侧突发性感音神经性听力损失病例。我们进一步回顾了关于突发性感音神经性听力损失治疗的现有文献，以及SSNHL与先前免疫接种和COVID-19感染的关联。最后，我们推测了SSNHL与辉瑞-生物科技公司的COVID-19疫苗之间潜在的潜在机制。
